Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582792 | 1.00 | PDE3A (0.52) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL223208 | 0.90 | PDE3A (0.54) | PDE3APDE4DSLC29A1LMNAMTOR | |
| Hydrochloric Acid SCHEMBL28104164 | 0.89 | PDE3A (0.53) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL23258348 | 0.88 | PDE3A (0.56) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL27966727 | 0.87 | PDE3A (0.54) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL12878163 | 0.85 | PDE3A (0.48) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL12891131 | 0.85 | PDE3A (0.48) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL5824290 | 0.84 | PDE3A (0.48) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL3759574 | 0.84 | POLA1 (0.44) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL19644955 | 0.82 | PDE4D (0.38) | PDE3APDE4DSLC29A1LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 424 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117157318-A | anti-HVEM antibodies | 免疫治疗有限公司 | 2023-12-01 | — | — | CN | claimed |
| EP-3980023-A1 | LIPID NANOPARTICLES CONTAINING PHARMACEUTICAL AND/OR NUTRACEUTICAL AGENTS AND METHODS THEREOF | Board of Regents, The University of Texas System (US) | 2022-04-13 | — | — | EP | claimed |
| EP-3915549-A1 | SENESCENCE INDUCERS FOR USE IN THE TREATMENT AND/OR PREVENTION OF VIRUS INDUCED DISEASES | Merck Patent GmbH (DE) | 2021-12-01 | — | — | EP | claimed |
| US-20210309740-A1 | BISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THERAPEUTIC USES THEREOF | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2021-10-07 | — | — | US | claimed |
| US-10189903-B2 | Bispecific chimeric antigen receptors and methods of use thereof to treat cancer | SEATTLE CHILDREN'S HOSPITAL (US) | 2019-01-29 | — | — | US | claimed |
| US-20170107285-A1 | BISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND ENCODING POLYNUCLEOTIDES THEREOF | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2017-04-20 | — | — | US | claimed |
| EP-2814846-A1 | BISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THERAPEUTIC USES THEREOF | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2014-12-24 | — | — | EP | claimed |
| WO-2013123061-A1 | BISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THERAPEUTIC USES THEREOF | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | WO | claimed |
| EP-2593122-A1 | PEPTIDE FOR USE IN THE TREATMENT OF BREAST CANCER AND/OR BONE METASTASES | Merck Patent GmbH (DE) | 2013-05-22 | — | — | EP | claimed |
| US-20130115210-A1 | Peptide for Use in the Treatment of Breast Cancer and/or Bone Metastases | MERCK PATENT GMBH (DE) | 2013-05-09 | — | — | US | claimed |
| US-20070280944-A1 | Use of 5,10-Methylene Tetrahydrofolate for the Treatment of Cancer | ADVENTRX PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | US | claimed |
| EP-1740182-A2 | USE OF 5,10-METHYLENE TETRAHYDROFOLATE FOR THE TREATMENT OF CANCER | Robbins, Joan M. (US) | 2007-01-10 | — | — | EP | claimed |
| US-20060154854-A1 | Molecules for targeting and releasing therapeutic compounds, and the use thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2006-07-13 | — | — | US | claimed |
| EP-1631592-A2 | MOLECULES FOR TARGETING AND RELEASING THERAPEUTIC COMPOUNDS, AND THE USE THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2006-03-08 | — | — | EP | claimed |
| WO-2005097086-A2 | USE OF 5,10-METHYLENE TETRAHYDROFOLATE FOR THE TREATMENT OF CANCER | ADVENTRX PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050034178-A1 | Stress-responsive induction of a therapeutic agent and methods of use | UNIVERSITY OF SOUTHERN CALIFORNIA | 2005-02-10 | — | — | US | claimed |
| WO-2004111090-A2 | MOLECULES FOR TARGETING AND RELEASING THERAPEUTIC COMPOUNDS, AND THE USE THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2004-12-23 | — | — | WO | claimed |
| WO-2001000791-A9 | STRESS-RESPONSIVE INDUCTION OF A THERAPEUTIC AGENT AND METHODS OF USE | UNIV SOUTHERN CALIFORNIA (US) | 2002-07-25 | — | — | WO | claimed |
| EP-1194527-A1 | STRESS-RESPONSIVE INDUCTION OF A THERAPEUTIC AGENT AND METHODS OF USE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2001000791-A1 | STRESS-RESPONSIVE INDUCTION OF A THERAPEUTIC AGENT AND METHODS OF USE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2001-01-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154854-A1 | Molecules for targeting and releasing therapeutic compounds, and the use thereof | BID, CD40, BCR | PDE3A 3756/4885PDE4D 2890/4885SLC29A1 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.